Issue 9, 2018

Synthesis of novel perillyl–dihydropyrimidinone hybrids designed for antiproliferative activity

Abstract

A series of fifteen novel dihydropyrimidinone hybrid compounds were synthesized in good yields via a multicomponent reaction combined with the Huisgen reaction. The antiproliferative activity was investigated against nine tumor cell lines, and four hybrid compounds (TGI < 10 μM) showed promising antiproliferative activity against the tumor cell lines OVCAR-3 (ovarian), UACC-62 (melanoma) and U251 (glioma). Several hybrid compounds assayed have high TGI values (TGI 147.92–507.82) for the human keratinocyte cell line (HaCat), which reveals selectivity to cancer cells.

Graphical abstract: Synthesis of novel perillyl–dihydropyrimidinone hybrids designed for antiproliferative activity

Supplementary files

Article information

Article type
Research Article
Submitted
26 May 2018
Accepted
27 Jul 2018
First published
31 Jul 2018

Med. Chem. Commun., 2018,9, 1553-1564

Synthesis of novel perillyl–dihydropyrimidinone hybrids designed for antiproliferative activity

V. Vendrusculo, V. P. de Souza, L. A. M. Fontoura, M. G. M. D'Oca, T. P. Banzato, P. A. Monteiro, R. A. Pilli, J. E. de Carvalho and D. Russowsky, Med. Chem. Commun., 2018, 9, 1553 DOI: 10.1039/C8MD00270C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements